Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2

Abstract

Background: Individuals with Chronic Inflammatory Diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2 vaccination platforms provide robust protection in immunocompetent individuals, the immunogenicity in CID patients on immunosuppression is not well established. Therefore, determining the potency of SARS-CoV-2 vaccines in the setting of immunosuppression is essential to risk-stratify CID patients with impaired protection and provide clinical guidance regarding medication management. Methods: We conducted a prospective assessment of mRNA-based vaccine immunogenicity in 133 adults with CIDs and 53 immunocompetent controls. Blood from participants over 18 years of age was collected before initial immunization and 1-2 weeks after the second immunization. Serum anti-SARS-CoV-2 spike (S) IgG+ binding, neutralizing antibody titers, and circulating S-specific plasmablasts were quantified to assess the magnitude and quality of the humoral response following vaccination. Results: Compared to immunocompetent controls, a three-fold reduction in anti-S IgG titers (P=0.009) and SARS-CoV-2 neutralization (p<0.0001) were observed in CID patients. B cell depletion and glucocorticoids exerted the strongest effect with a 36- and 10-fold reduction in humoral responses, respectively (p<0.0001). Janus kinase inhibitors and antimetabolites, including methotrexate, also blunted antibody titers in multivariate regression analysis (P<0.0001, P=0.0023, respectively). Other targeted therapies, such as TNF inhibitors, IL-12/23 inhibitors, and integrin inhibitors, had only modest impacts on antibody formation and neutralization. Conclusions: CID patients treated with immunosuppressive therapies exhibit impaired SARS-CoV-2 vaccine-induced immunity, with glucocorticoids and B cell depletion therapy more severely impeding optimal responses.

Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy

“…For example, patients with autoimmune conditions treated with B cell-depleting antibodies have predictably diminished humoral responses to vaccination, whereas responses by patients on anti-TNF⍺ therapies are less affected 19 . As another example, organ transplant recipients mount very poor antibody responses to the first mRNA immunization relative to healthy individuals 20 , but improve somewhat after the second immunization 21 .…”

Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response

“…in one preprint rituximab, glucocorticoids and possibly JAK inhibitors). 4 This led rheumatologists to address the question of how to deal with patients who show insufficient immunogenicity after vaccination.…”

Differences in IgG antibody responses following BNT162b2 and mRNA-1273 Vaccines

“…Two participants did not seroconvert following their second dose. In the first non-seroconverting participant, who was receiving a monoclonal antibody (rituximab) against CD20, SARS-CoV-2 antibodies were not detected 28 days following the second dose (BNT162b2) (10). In the second non-seroconverting participant, who was receiving an agent (fingolimod-phosphate) that blocks lymphocytes' ability to emerge from lymph nodes, SARS-CoV-2 antibodies were not detected 21 days following the second dose (mRNA-1273) (11).…”